AI & Multi-Omics in Pharmacogenomics: PGxAI’s New Review

Read the full article in Mayo Clinic Proceedings: Digital Health — our new open-access review, “AI and Multi-Omics in Pharmacogenomics: A New Era of Precision Medicine,” is now live.

Why it matters?

— Hidden drug-response signals, revealed. Layering metabolomics on top of genomic profiles uncovers actionable patterns invisible in isolation.

— Proven uplift. Variational auto-encoders, graph neural networks and GPT-style LLMs already boost prediction accuracy by 5–20 % in real-world datasets.

— Clinical wins today. Oncology, cardiology and psychiatry case studies show multi-omics models reshaping treatment decisions—no longer theory, but practice.

— Pathways past adoption hurdles. From federated learning to explainable AI, we map concrete workflows that respect data privacy while delivering bedside impact.

We wrote this review to distill fast-moving research into actionable guidance for clinicians, data scientists and health-tech innovators. The PDF is free to download—use it to sharpen your own precision-medicine strategy without paywall friction.

Ready to dig deeper, test code or discuss use-cases? Drop us a line via the contact form or comment on the article thread—we’re keen to collaborate.